Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives $327.40 Consensus Price Target from Analysts
Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the four analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month […]
Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the four analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month […]
